◆ TICKERBASEOpen interactive view →
◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

HomeAll stocksG › GKOS

Glaukos Corp (GKOS) Financial History

20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.

HEALTHCARE · MEDICAL DEVICES · DATA UPDATED 2026-07-31

Glaukos Corp (GKOS) operates in the MEDICAL DEVICES industry and is headquartered in Aliso Viejo, United States with about 1,094 employees. Its market capitalization is roughly $10 billion. In the fiscal year ended 2025-12-31, GKOS reported $507M in revenue and ($188M) in net income.

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally.

Interactive charts & full statements → Open the GKOS valuation workbench →

GKOS Revenue & Earnings History — Annual Income Statement

Income statementTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Total Revenue$614M$507M$383M$315M$283M$294M$225M$237M$181M$159M$114M$72M$46M$21M$2M
Gross Profit$485M$393M$289M$239M$214M$227M$133M$198M$156M$138M$98M$59M$34M$18M$1M
Gross Margin %79.0%77.5%75.5%76.0%75.6%77.3%59.2%83.7%86.2%86.8%85.9%81.9%75.0%87.9%31.9%
Operating Income (EBIT)($80M)($87M)($122M)($129M)($82M)($33M)($124M)($50M)($13M)($2M)$4M($10M)($13M)($14M)($22M)
Operating Margin %-13.0%-17.1%-31.9%-40.9%-29.1%-11.2%-54.9%-21.2%-7.2%-1.4%3.7%-14.4%-28.9%-67.8%-909.8%
Net Income($188M)($188M)($146M)($135M)($99M)($50M)($120M)$15M($13M)$0M$5M($37M)($12M)($13M)($19M)
Net Margin %-30.6%-37.0%-38.2%-42.8%-35.1%-16.9%-53.5%6.5%-7.1%-0.1%4.0%-51.9%-26.6%-60.3%-795.8%
EBITDA($152M)($146M)($96M)($82M)($49M)($1M)($84M)($38M)($7M)$5M$9M($33M)($9M)($13M)($21M)
Earnings Per Share (EPS)$-3.25$-3.28$-2.77$-2.78$-2.09$-1.07$-2.70$0.37$-0.37$-0.00$0.12$-2.13$-0.49$-0.51$-9.73
Shares Outstanding (M)58M57M53M48M47M46M44M41M35M34M36M17M25M2M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GKOS Quarterly Revenue & Earnings — Last 8 Quarters

Quarterly income statement2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Total Revenue$186M$151M$143M$134M$124M$107M$105M$97M
Gross Profit$152M$117M$111M$105M$97M$82M$77M$74M
Gross Margin %81.7%77.9%77.8%78.4%78.3%77.2%72.9%76.6%
Operating Income (EBIT)($17M)($20M)($27M)($16M)($23M)($21M)($29M)($25M)
Operating Margin %-9.3%-13.2%-18.9%-12.3%-18.3%-19.4%-27.2%-25.5%
Net Income($18M)($20M)($134M)($16M)($20M)($18M)($34M)($21M)
Net Margin %-9.9%-13.1%-93.4%-12.2%-15.8%-17.0%-31.8%-22.1%
EBITDA($17M)($5M)($125M)($5M)($9M)($7M)($22M)($10M)
Earnings Per Share (EPS)$-0.31$-0.34$-2.32$-0.28$-0.34$-0.32$-0.60$-0.39
Shares Outstanding (M)58M58M58M57M57M57M56M55M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GKOS Free Cash Flow History

Cash flowTTM → 2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Cash from Operations (CFO)($1M)($15M)($61M)($58M)($33M)$25M($23M)$0M$19M$26M$12M($2M)($7M)($13M)($20M)
Capital Expenditures (CapEx)$12M$8M$6M$20M$30M$48M$7M$5M$10M$6M$6M$1M$1M$1M$1M
Free Cash Flow (FCF)($12M)($23M)($68M)($78M)($63M)($23M)($30M)($5M)$9M$19M$6M($3M)($8M)($14M)($21M)
FCF Margin %-1.9%-4.5%-17.6%-24.8%-22.4%-7.8%-13.3%-2.1%4.7%12.0%5.3%-4.3%-17.5%-67.6%-864.1%
Dividends Paid$6M$27M$263M$13M$0M$0M$0M

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GKOS Quarterly Free Cash Flow — Last 8 Quarters

Quarterly cash flow2026-06-302026-03-312025-12-312025-09-302025-06-302025-03-312024-12-312024-09-30
Cash from Operations (CFO)$15M($13M)$7M($10M)$7M($19M)$1M($10M)
Capital Expenditures (CapEx)$3M$4M$3M$2M$1M$2M$2M$1M
Free Cash Flow (FCF)$12M($16M)$4M($12M)$6M($20M)($1M)($11M)
FCF Margin %6.5%-10.9%2.8%-8.8%4.7%-19.2%-1.2%-11.4%

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

GKOS Balance Sheet History

Balance sheet2026-06-302025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-31
Total Assets$921M$893M$975M$940M$1.1B$1.1B$1.0B$818M$207M$166M$134M$117M$26M$31M$5M
Cash & Cash Equivalents$114M$91M$170M$93M$120M$101M$97M$62M$30M$25M$6M$22M$2M$7M$2M
Total Liabilities$238M$237M$208M$479M$544M$542M$338M$145M$33M$28M$17M$21M$187M$180M$14M
Total Debt (Short + Long-Term)$0M$0M$2M$285M$282M$281M$191M$2M$0M$0M$0M$10M$19M$18M$0M
Total Shareholders' Equity$682M$656M$767M$462M$530M$587M$667M$673M$174M$138M$117M$95M($151M)($141M)($3M)

USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive GKOS viewer.

GKOS Metric Deep Dives

Other Companies in MEDICAL DEVICES

This page in other languages: עברית · Русский · Español · Português · 中文 · العربية · Français · Italiano · 日本語 · Deutsch · فارسی · हिन्दी

← GKLAll “G” companiesGKP →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.